Jefferies Financial Group Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Key Points

• Jefferies Financial Group has raised its target price for Insmed (NASDAQ: INSM) from $129 to $148, suggesting a potential upside of 21.31% based on the stock's previous close.
• Insmed received favorable ratings from several firms, with the consensus price target now at $121.71 and an average rating of "Moderate Buy" among analysts.
• The company reported $107.42 million in revenue for the last quarter, a 18.9% increase compared to the previous year, but missed earnings estimates with a loss of ($1.70) EPS.

Insmed (NASDAQ:INSM - Get Free Report) had its target price lifted by investment analysts at Jefferies Financial Group from $129.00 to $148.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Jefferies Financial Group's price target would suggest a potential upside of 21.31% from the stock's previous close.

INSM has been the topic of several other research reports. Citigroup raised Insmed to a "buy" rating in a research note on Tuesday, June 10th. JPMorgan Chase & Co. increased their target price on Insmed from $90.00 to $111.00 and gave the company an "overweight" rating in a research note on Tuesday, July 8th. Mizuho increased their target price on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday. Morgan Stanley increased their target price on Insmed from $102.00 to $108.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Finally, HC Wainwright increased their target price on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and a consensus price target of $121.71.

Insmed Price Performance

Shares of INSM stock opened at $122.00 on Wednesday. The stock's fifty day moving average is $100.45 and its 200-day moving average is $82.92. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The stock has a market capitalization of $25.79 billion, a PE ratio of -21.37 and a beta of 0.95. Insmed has a 52 week low of $60.40 and a 52 week high of $122.03.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same period last year, the company earned ($1.94) EPS. The company's revenue was up 18.9% compared to the same quarter last year. Equities research analysts expect that Insmed will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at approximately $8,352,401.94. This trade represents a 52.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 129,805 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. The trade was a 35.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 537,440 shares of company stock valued at $50,436,948 in the last ninety days. Corporate insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. grew its stake in Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Insmed by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after purchasing an additional 219,131 shares in the last quarter. Capital International Investors grew its stake in Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Insmed by 109.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after purchasing an additional 1,799,382 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.